Roche consumes more of Aileron’s stapled diet, bulking up $1.1Bn peptide deal
This article was originally published in Scrip
Executive Summary
Aileron Therapeutics, which is focused on a new class known as "stapled peptide" drugs, has announced that a collaboration it formed with Roche in 2010 has been expanded.